Healthcare Business

child with cancer

With New Cash and Cancer Targets, Analyst Sees Almost 200% Upside in Sierra Oncology

Sierra Oncology Inc. (NASDAQ: SRRA) is far from a household name for investors who delve into health care, pharmaceuticals and biotech. In fact, Sierra would have to be considered quite ...
Read Full Story »
research

Tuesday’s Top Biopharma Movers

A few biopharma companies made massive runs on Tuesday morning. The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the ...
Read Full Story »
Medical vaccine in shoulder, vaccination

Why This FDA Approval for Valeant Is Not as Good as First Thought

Valeant Pharmaceuticals International Inc. (NYSE: VRX) received a key U.S. Food and Drug Administration (FDA) approval early on Thursday, but it seems to be a mixed blessing. Initially shares were higher ...
Read Full Story »
Prescription drugs

How Alexion’s Pipeline Is Driving Earnings

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) released its most recent earnings report before the markets opened on Thursday. This company posted $1.26 in earnings per share (EPS) on $831 million in ...
Read Full Story »
automatic inspection machine

How Gene Editing Just Got Rocked by Major Patent Ruling

The possibilities around gene editing are almost endless. Some of the goals and hopes around gene editing sound like they were pulled right out of a science fiction or futuristic ...
Read Full Story »
tired frustrated unhappy business person

Merck Delivers Even More Disappointing News in Alzheimer’s Study

Merck & Co. (NYSE: MRK) saw its shares slip on Wednesday after the firm reported that it will be halting its mid-to-late-stage clinical trial for the treatment of Alzheimer’s disease. ...
Read Full Story »
100 dollar bills

Why Evoke Pharma Shares Are Exploding

Evoke Pharma Inc. (NASDAQ: EVOK) saw its shares make a huge gain on Wednesday after the company issued an update that it received from the U.S. Food and Drug Administration ...
Read Full Story »
thumbs up and down

What Analysts Are Saying About Teva Pharmaceutical After Earnings

Teva Pharmaceutical International Inc. (NYSE: TEVA) reported fourth-quarter and full-year 2016 results before markets opened Monday. Only a few analysts weighed in initially, but the consensus is slowly growing more ...
Read Full Story »
Woman sitting alone and depressed, sad, miserable

Can Sage Therapeutics Press Even Further With Its Depression Trial?

Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw a handy gain on Monday after the company announced a successful mid-stage trial for the treatment of major depressive disorder (MDD). Specifically the ...
Read Full Story »
U Turn

Can Zosano Pharma Turn Itself Around With This Late-Stage Migraine Trial Win?

Zosano Pharma Corp. (NASDAQ: ZSAN) saw its shares absolutely skyrocket on Monday after the firm gave an update on its late-stage trial for the treatment of migraines. Basically, the lead ...
Read Full Story »
Medicine pills

How Rosy Is the Outlook for Teva Pharmaceutical?

Teva Pharmaceutical International Inc. (NYSE: TEVA) reported fourth-quarter and full-year 2016 results before markets opened Monday. The company reported quarterly adjusted diluted earnings per share (EPS) of $1.38 and revenues ...
Read Full Story »
Wow

Major Biotechs Scare Off Loads of Short Sellers

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Pair of dice

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Prescription drugs

What Is Driving CVS Revenue Growth?

When CVS Health Corp. (NYSE: CVS) reported its fourth-quarter financial results before the markets opened on Thursday, the company posted $1.71 in earnings per share (EPS) and $46.0 billion in ...
Read Full Story »
Jon's friends

Is This the Big Turnaround Acorda Needs?

Shares of Acorda Therapeutics Inc. (NASDAQ: ACOR) saw a handy gain in early trading on Thursday after the company reported results from its late-stage Parkinson’s trial. Basically, the company announced Phase ...
Read Full Story »